Pacific Biosciences of California Inc. (NASDAQ:PACB) went down by -12.99% from its latest closing price compared to the recent 1-year high of $53.69. The company’s stock price has collected -25.60% of loss in the last five trading sessions. Press Release reported on 02/18/21 that Pacific Biosciences Sequel II Systems Deployed to Scale-Up Global Viral Surveillance Initiatives Focused on COVID-19
Is It Worth Investing in Pacific Biosciences of California Inc. (NASDAQ :PACB) Right Now?
Pacific Biosciences of California Inc. (NASDAQ:PACB) scored a price-to-earnings ratio above its average ratio, recording 445.71 x from its present earnings ratio. Plus, the 36-month beta value for PACB is at 1.24. Opinions of the stock are interesting as 3 analysts out of 5 who provided ratings for Pacific Biosciences of California Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 2 rated it as “hold,” and 0 as “sell.”
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The average price from analysts is $50.80, which is $9.81 above the current price. PACB currently public float of 184.14M and currently shorts hold a 7.06% ratio of that float. Today, the average trading volume of PACB was 5.16M shares.
PACB’s Market Performance
PACB stocks went down by -25.60% for the week, with a monthly jump of 3.11% and a quarterly performance of 144.07%, while its annual performance rate touched 793.56%. The volatility ratio for the week stands at 8.77% while the volatility levels for the past 30 days are set at 9.10% for Pacific Biosciences of California Inc.. The simple moving average for the period of the last 20 days is -4.16% for PACB stocks with a simple moving average of 165.39% for the last 200 days.
Analysts’ Opinion of PACB
Many brokerage firms have already submitted their reports for PACB stocks, with Piper Sandler repeating the rating for PACB by listing it as a “Overweight.” The predicted price for PACB in the upcoming period, according to Piper Sandler is $52 based on the research report published on February 11th of the current year 2021.
Piper Sandler, on the other hand, stated in their research note that they expect to see PACB reach a price target of $12. The rating they have provided for PACB stocks is “Neutral” according to the report published on November 03rd, 2020.
JP Morgan gave a rating of “Overweight” to PACB, setting the target price at $15 in the report published on October 02nd of the previous year.
PACB Trading at 15.21% from the 50-Day Moving Average
After a stumble in the market that brought PACB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -30.27% of loss for the given period.
Volatility was left at 9.10%, however, over the last 30 days, the volatility rate increased by 8.77%, as shares surge +0.05% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +66.25% upper at present.
During the last 5 trading sessions, PACB fell by -25.60%, which changed the moving average for the period of 200-days by +1,020.96% in comparison to the 20-day moving average, which settled at $39.07. In addition, Pacific Biosciences of California Inc. saw 44.33% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at PACB starting from ORDONEZ KATHY, who sale 220,771 shares at the price of $47.99 back on Feb 16. After this action, ORDONEZ KATHY now owns 21,875 shares of Pacific Biosciences of California Inc., valued at $10,595,810 using the latest closing price.
Botstein David, the Director of Pacific Biosciences of California Inc., sale 160,000 shares at $49.62 during a trade that took place back on Feb 12, which means that Botstein David is holding 0 shares at $7,939,764 based on the most recent closing price.
Stock Fundamentals for PACB
Current profitability levels for the company are sitting at:
- -132.31 for the present operating margin
- +41.28 for the gross margin
The net margin for Pacific Biosciences of California Inc. stands at +37.27. The total capital return value is set at -42.25, while invested capital returns managed to touch 12.40. Equity return is now at value -71.30, with -22.80 for asset returns.
Based on Pacific Biosciences of California Inc. (PACB), the company’s capital structure generated 12.52 points at debt to equity in total, while total debt to capital is 11.13. Total debt to assets is 10.15, with long-term debt to equity ratio resting at 12.52. Finally, the long-term debt to capital ratio is 11.13.
When we switch over and look at the enterprise to sales, we see a ratio of 50.80, with the company’s debt to enterprise value settled at 0.01. The receivables turnover for the company is 4.91 and the total asset turnover is 0.28. The liquidity ratio also appears to be rather interesting for investors as it stands at 16.95.